VVOS · Vivos Therapeutics, Inc.
$0.40
-0.01 (-2.65%)
At close · Jul 22
Going-concern doubt
— flagged May 20, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Without additional financing, these factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed May 20, 2026
Market Cap
$5.61M
Shares
13.89M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| R. Kirk Huntsman | CEO | $1,306,906 |
| Bradford Amman | CFO | $705,919 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| R. Kirk Huntsman | CEO | $657,701 |
| Bradford Amman | CFO | $400,040 |
| G. Dave Singh | Founder, Chief Medical Officer and Director | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| R. Kirk Huntsman | CEO | $937,850 |
| Bradford Amman | CFO | $492,919 |
| G. Dave Singh | Founder, Chief Medical Officer and Director | $77,491 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Bradford Amman | CFO | $1,106,092 |
| R. Kirk Huntsman | CEO | $1,077,149 |
| G. Dave Singh | Founder, Chief Medical Officer and Director | $447,003 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| R. Kirk Huntsman | CEO | $455,336 |
| G. Dave Singh | Founder, Chief Medical Officer and Director | $298,507 |
| Bradford Amman | CFO | $268,938 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Bradford Amman | CFO | $297,220 |
| G. Dave Singh | Founder, Chief Medical Officer and Director | $294,407 |